A clinical study to assess the safety and immune response with Typhoid conjugate vaccine of BE when compared with a licensed Typhoid conjugate vaccine.

Phase 2

Completed

• Conditions: Health Condition 1: Z23- Encounter for immunization

• Registration Number: CTRI/2018/11/016419
• Lead Sponsor: Biological E Limited

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2019-04-10
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 595

Inclusion Criteria

1. Healthy subjects of either gender between >=6 months to <64 years of age at the time of vaccination

2. Subject or Subjectâ??s Parent(s) or LAR who after the nature of the study has been explained to them, have given written consent according to local regulatory requirements.

3. Subject or Subjectâ??s Parent(s) or LARâ??s ability to understand information relevant to participation in the study and abide with the requirements of the subject diary and other study procedures;

4. Individuals in good health as determined by the outcome of medical history, physical examination based on clinical judgment of the investigator.

5. Negative to urine pregnancy test for female subjects of childbearing potential. Female of childbearing potential is defined as a pre-menopausal female capable of becoming pregnant. This does not include females who meet any of the following conditions: (1) menopause at least 2 years earlier, (2) tubal ligation at least 1 year earlier, or (3) total hysterectomy.

Exclusion Criteria

1. Individuals who have a previously ascertained or suspected disease caused by Salmonella typhi;

2. Individuals who have history of household contact with/and or intimate exposure to an individual with laboratory confirmed S. typhi;

3. Individuals who have previously received any vaccines against typhoid fever (either oral live attenuated or injectable vaccines);

4. Individuals with body temperature >=100.4°F (>=38.0°C) within 3 days of intended study immunization;

5. Individuals with any serious chronic or progressive disease according to judgment of the investigator (e.g., neurological, neoplasm, insulin dependent diabetes, cardiac, renal or hepatic disease);

6. Subject or Subjectâ??s Parent(s) or LAR unwillingness or inability to understand and follow required study procedures, keep appointments, or are planning to relocate during the study period;

7. Individuals with history of any illness or any laboratory abnormality that, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the subjects due to participation in the study;

8. Subject with suspected or known history of an autoimmune disorder or any other known or suspected impairment /alteration of the immune system, or under immunosuppressive therapy including use of systemic corticosteroids or chronic use of inhaled high-potency corticosteroids within the previous 30 days;

9. Subject with a known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time or history of receipt of anti-coagulants in the past 3 weeks;

10. History of allergy or allergic reaction to any vaccine-related component;

11. Individuals participating in any other clinical trial within 30 days prior to first study visit or intent to participate in another clinical study at any time during the conduct of this study;

12. Women who are pregnant or breast-feeding or of childbearing age who have not used or do not plan to use acceptable birth control measures, for the duration of the study. Female of childbearing potential or age is defined as a pre-menopausal female capable of becoming pregnant. This does not include females who meet any of the following conditions: (1) menopause at least 2 years earlier, (2) tubal ligation at least 1 year earlier, or (3) total hysterectomy.

13. Any other reason that in the opinion of the investigator may interfere with the evaluation required by the study objectives.

Study & Design

• Study Type: Interventional
• Study Design: Not specified